Skip Navigation

Journal of Antimicrobial Chemotherapy 2008 62(Supplement 2):ii55-ii63; doi:10.1093/jac/dkn352
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Livermore, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Livermore, D. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

This article appears in the following Journal of Antimicrobial Chemotherapy issue: The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project 1999/2000-2006/7 [View the issue table of contents]

Articles

Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001–06

David M. Livermore1,*, Russell Hope1, Geraldine Brick1, Mark Lillie1, Rosy Reynolds2 on behalf of the BSAC Working Parties on Resistance Surveillance

1 Health Protection Agency Centre for Infections, 61 C olindale Avenue, London NW9 5EQ, UK 2 Department of Medical Microbiology, Southmead Hospital, Bristol BS10 5NB, UK


* Correspondence address. Antibiotic Resistance Monitoring and Reference Laboratory, HPA Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK. Tel: +44-20-8327-7223; Fax: +44-20-8327-6264; E-mail: david.livermore{at}hpa.org.uk

Background: Pseudomonas and Acinetobacter spp. are important opportunists, notorious for resistance. Pseudomonas spp. are collected in the British Society for Antimicrobial Chemotherapy (BSAC) bacteraemia surveillance, with Acinetobacter spp. and Stenotrophomonas maltophilia well represented in the ‘other Gram-negatives’ group.

Methods: Data for collected isolates were reviewed together with LabBase bacteraemia reports to the Health Protection Agency (HPA). Isolates with unusual resistances were subjected to molecular investigation.

Results: From 2001 to 2006, the BSAC surveillance collected 1226 Pseudomonas aeruginosa, 240 Acinetobacter spp.—125 of them Acinetobacter calcoaceticus/baumannii (Acb) complex—and 165 S. maltophilia. Among P. aeruginosa, non-susceptibility rates to β-lactams and gentamicin fluctuated, without trend, below 10%; those to ciprofloxacin ranged from 16% to 22%. One P. aeruginosa isolate from 2001 had VIM-2 metallo-β-lactamase. For Acb, the BSAC data indicated frequent non-susceptibility, except to imipenem, where only five non-susceptible isolates were collected, all after 2003, four of them belonging to the OXA-23 clone 1 lineage which is prevalent in Southeast England. Reports to the HPA indicated rising imipenem non-susceptibility in Acb (P < 0.0001). Co-trimoxazole retained near-universal activity against S. maltophilia. Among new antibiotics, doripenem MICs were ≤4 mg/L for most imipenem-resistant P. aeruginosa but ≥16 mg/L for Acb OXA-23 clone 1. Ceftobiprole had higher MICs than ceftazidime for P. aeruginosa, but 81% of the isolates were inhibited at ≤4 mg/L. Tigecycline had activity against most Acb, including OXA-23 clone 1, and also against S. maltophilia.

Conclusions: Most P. aeruginosa from bacteraemias in the UK and Ireland remain relatively susceptible by international standards; in contrast, multiresistance is widespread in Acb, with imipenem non-susceptibility emerging.

Keywords: bacteraemia , Pseudomonas aeruginosa , Acinetobacter spp. antibiotic resistance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
R. Reynolds
Antimicrobial resistance in the UK and Ireland
J. Antimicrob. Chemother., September 1, 2009; 64(suppl_1): i19 - i23.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. R. White and on behalf of the BSAC Working Parties on Resistanc
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: a successful collaborative model
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii3 - ii14.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. Reynolds, R. Hope, L. Williams, and on behalf of the BSAC Working Parties on Resistanc
Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii15 - ii28.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. Reynolds, P. C. Lambert, P. R. Burton, and on behalf of the BSAC Extended Working Parties on
Analysis, power and design of antimicrobial resistance surveillance studies, taking account of inter-centre variation and turnover
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii29 - ii39.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.